TrakCel announced today it was selected as the organization responsible for tracking and documentation of cell and gene therapy products for the Northern Alliance Advanced Therapies Treatment Centre. 

The Northern Alliance is a partnership of advanced therapies companies, NHS organizations and academic groups in the North of England and Scotland. The partnership of twenty organizations will be led by Newcastle upon Tyne NHS Hospitals NHS Foundation Trust and the Scottish National Blood Transfusion Service. The alliance has received an Industrial Strategy Challenge Fund three-year grant award from Innovate UK. The grant totals £7 million with an expected additional £2 million contributions from commercial partners.

The Northern Alliance has been tasked with facilitating the development, commercialization and adoption of cell, gene and tissue engineered therapies in the UK. Specifically, this collaboration will create ‘state-of-art’ infrastructure that includes technology, logistics, storage, manufacturing and supply of clinical sites, evaluation, funding and adoption.

“TrakCel now provides tracking and orchestration to numerous global cell and gene therapy companies across the industry. It is now established across the global industry that all major cell therapy projects require a traceability and management solution for operating their clinical development and furthering their commercialisation strategies,” said Ravi Nalliah, chief executive officer, TrakCel. “As a result, the TrakCel platform will be critical to the success of the development of therapies by the Northern Alliance that could help countless patients across the UK and globally. This is a responsibility that we take incredibly seriously.”